The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

Anti-PD-1 therapy (PD1) either alone or with anti-CTLA-4 (CTLA4), has high initial response rates, however 20% of patients (pts) with complete response (CR) and 30% with partial response (PR) within 12 months of treatment experience subsequent disease progression by 6 years. The nature and optimal m...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of cancer (1990) 2024-01, Vol.196, p.113441, Article 113441
Hauptverfasser:	Hepner, Adriana, Versluis, Judith M, Wallace, Roslyn, Allayous, Clara, Brown, Lauren Julia, Trojaniello, Claudia, Gerard, Camille Lea, Jansen, Yanina Jl, Bhave, Prachi, Neyns, Bart, Haydon, Andrew, Michielin, Olivier, Mangana, Joanna, Klein, Oliver, Shoushtari, Alexander N, Warner, Allison Betof, Ascierto, Paolo Antonio, McQuade, Jennifer Leigh, Carlino, Matteo S, Zimmer, Lisa, Lebbe, Celeste, Johnson, Douglas B, Sandhu, Shahneen, Atkinson, Victoria, Blank, Christian U, Lo, Serigne N, Long, Georgina V, Menzies, Alexander M
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies - therapeutic use CTLA-4 Antigen - immunology Humans Immunotherapy Melanoma - pathology Melanoma - therapy Middle Aged Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!